A new cancer treatment for cancer: The Watauga Medical Center pharmacy

Posted May 06, 2018 08:51:16 A cancer treatment is being tested at the Watauga Hospital Medical Center Pharmacy in West Palm Beach, Florida.

The drug, called Rovid-19, is being used to treat two types of cancer.

The treatment is expected to be available for use within three to five years.

“The treatment we’re going to be able to offer patients is a really important tool in the fight against this disease,” said Dr. Jeffrey T. Rocha, who is leading the clinical trial at the hospital.

“The goal is to have this drug available in three to six months.

It’s a treatment that will make a real difference to a person who’s going to go into remission.

It will be used for years to come.”

A few patients have already enrolled in the trial, and others are waiting for the results.

The trial has been underway for the past several months and it is expected that the trial will be completed in about five years, according to Dr. Rachael Fiedler, chief of the division of clinical trials for the National Cancer Institute.

“It is a new treatment that we’re very excited about,” she said.

“It’s not like it’s been around for decades.

This is a drug that is going to take a little bit longer to be ready for people to be on it.”

The drug was developed by a company called MMC Pharmaceuticals.

MMC is based in New Jersey.

The company received $9.9 million in funding from the National Institutes of Health.

The study was designed to test whether the drug could cure patients who have Stage 4 and Stage 5 cervical cancer, and to test the drug’s safety and efficacy in patients with Stage 2 and Stage 3 cancers.

Tests were performed in March and April at the Womack Medical Center in Watauga, where patients received three weeks of treatment.

The patients had their cancers removed and were given two weeks of Roviside-19.

The two groups of patients were then treated with a standard chemo-therapy regimen that includes chemotherapy and radiation, as well as surgery to remove tumors.

The cancer cells in the tumors were removed, and the treatment was continued with chemotherapy.

A new type of cancer was identified in one of the patients, and it was successfully treated.

“So this is a major milestone for our study,” Dr. T.J. Hargrove, MMC’s CEO, said.

“This is really a very, very exciting opportunity,” he added.

“We have a lot of cancer patients who are having their cancer treated at this point in time, and this is really an important step in their journey to cancer remission.

And we are very excited that we can help them.”

The Rovids are also being tested in the lab, where researchers are trying to figure out if the drug can treat cancers in the brain and pancreas.

The FDA approved the drug in October 2018, and a small trial was started in February 2019, according the FDA.

The new trial is scheduled to last six months, according Dr. Fiedlinger.

The clinical trial was approved by the U.S. Food and Drug Administration in February 2020.

“This trial will provide important data that will help us better understand the safety and effectiveness of this treatment in patients who need it most,” said Mary Ellen Capps, the FDA’s chief medical officer.